SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-170277
Filing Date
2022-06-08
Accepted
2022-06-08 17:00:55
Documents
12
Period of Report
2022-06-07
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d368711d8k.htm   iXBRL 8-K 24575
  Complete submission text file 0001193125-22-170277.txt   150296

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alrn-20220607.xsd EX-101.SCH 2863
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE alrn-20220607_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alrn-20220607_pre.xml EX-101.PRE 11712
6 EXTRACTED XBRL INSTANCE DOCUMENT d368711d8k_htm.xml XML 3562
Mailing Address 285 SUMMER STREET UNIT 101 BOSTON MA 02210
Business Address 285 SUMMER STREET UNIT 101 BOSTON MA 02210 617-995-0900
AILERON THERAPEUTICS INC (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 221004101
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences